

Claims:

Claims 1-39 (Cancelled).

1 ~~40~~. (Previously Presented) An antibody comprising:

a) a variable region comprising six complementarity determining regions (CDRs) from an antigen-specific donor antibody of a rodent and acceptor framework comprising amino acid residues from an Old World Ape, wherein at least one CDR-contacting amino acid residue from the acceptor framework is replaced with a corresponding residue from the donor framework, and wherein said CDR-contacting residue contacts a CDR residue within said antibody by the group selected from coming within the van der Waals radius of said CDR residue, a salt bridge and a hydrophobic interaction; and

b) at least one constant region from human, and

wherein said antibody has a specific binding avidity that is within about three-fold of the specific binding avidity of said antigen-specific donor antibody.

2 ~~41~~. (Previously Presented) The antibody of claim ~~40~~<sup>1</sup>, wherein the rodent is mouse.

3 ~~42~~. (Previously Presented) The antibody of claim ~~40~~<sup>1</sup>, wherein the rodent is rat.

4 ~~43~~. (Previously Presented) The antibody of claim ~~40~~<sup>1</sup>, wherein the Old World Ape is *Pan troglodytes*, *Pan paniscus* or *Gorilla gorilla*.

5 ~~44~~. (Previously Presented) The antibody of claim ~~40~~<sup>1</sup>, wherein the Old World Ape is *Pan troglodytes*.

45. (Cancelled).

46. (Cancelled).

47. (Cancelled).

6 ~~48~~. (Previously Presented) The antibody of claim ~~40~~<sup>1</sup>, wherein the acceptor framework comprises a light (VL) and heavy (VH) chain region each comprising four acceptor

framework regions (framework I, II, III, and IV), and wherein the VH acceptor framework I, II, III and IV are from chimpanzee.

7 ~~49~~<sup>6</sup>. (Previously Presented) The antibody of claim ~~48~~<sup>6</sup>, wherein the VH acceptor framework I, II and III comprise an amino acid sequence as set forth in SEQ ID NOs: 10, 11, 12, 13, 14, 15, 16, 17 or 18.

8 ~~50~~<sup>6</sup>. (Previously Presented) The antibody of claim ~~48~~<sup>6</sup>, wherein the VH acceptor framework IV comprises an amino acid sequence as set forth in SEQ ID NOs: 81, 82, 83, 84 or 85.

9 ~~51~~<sup>1</sup>. (Previously Presented) The antibody of claim ~~40~~<sup>1</sup>, wherein VL comprises segments V $\kappa$  and V $\lambda$ , and wherein V $\kappa$  comprises four acceptor framework regions (framework I, II, III, and IV), and wherein V $\kappa$  acceptor framework I, II, III and IV are from chimpanzee.

10 ~~52~~<sup>9</sup>. (Previously Presented) The antibody of claim ~~51~~<sup>9</sup>, wherein V $\kappa$  acceptor framework I, II, and III comprise an amino acid sequence as set forth in SEQ ID NOs: 28, 29, 30, 31, 32, 33, 34, 35 or 36.

11 ~~53~~<sup>9</sup>. (Previously Presented) The antibody of claim ~~51~~<sup>9</sup>, wherein V $\kappa$  acceptor framework IV comprises an amino acid sequence as set forth in SEQ ID NOs: 86 or 87.

54. (Withdrawn) The antibody of claim 40, wherein the acceptor framework comprises a light (VL) and heavy (VH) chain region each comprising four framework regions (framework I, II, III, and IV), and wherein the VH acceptor framework I, II, III and IV are from cynomolgus.

55. (Withdrawn) The antibody of claim 54, wherein the VH acceptor framework I, II and III comprise an amino acid sequence as set forth in SEQ ID NOs: 45, 46, 47, 48, 49, 50, 51 or 52.

56. (Withdrawn) The antibody of claim 54, wherein the VH acceptor IV comprises an amino acid sequence as set forth in SEQ ID NOs: 88, 89, 90, 91, 92 or 93.

57. (Withdrawn) The antibody of claim 54, wherein the VL comprises segments V $\kappa$  and V $\lambda$ , and wherein V $\kappa$  comprises four acceptor framework regions (framework I, II, III, and IV), and wherein V $\kappa$  acceptor framework I, II, III and IV are from cynomolgus.

58. (Withdrawn) The antibody of claim 57, wherein V $\kappa$  acceptor framework I, II and III comprise an amino acid sequence as set forth in SEQ ID NOs: 59, 60, 61, 62, 63 or 64.

59. (Withdrawn) The antibody of claim 57, wherein the V $\kappa$  acceptor framework IV comprises an amino acid sequence as set forth in SEQ ID NOs: 94, 95 or 96.

12 60. (Previously Presented) The antibody of claim 40, wherein the amino acid sequence of the complete light chain is set forth in SEQ ID NO: 68 and the amino acid sequences of the heavy chain is set forth in SEQ ID NO: 70.

13 61. (Previously Presented) The antibody of claim 40, wherein the amino acid sequence of the complete light chain is set forth in SEQ ID NO: 73 and the amino acid sequences of the heavy chain is set forth in SEQ ID NO: 74.

14 62. (Previously Presented) The antibody of claim 40, wherein the amino acid sequence of the complete light chain is set forth in SEQ ID NO: 77 and the amino acid sequences of the heavy chain is set forth in SEQ ID NO: 78.

63. (Cancelled).

64. (Withdrawn) A method for making an antibody having reduced immunogenicity in humans comprising grafting all six CDRs from antigen-specific rodent antibodies onto homologous Old World Ape acceptor frameworks.